Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030056 · ClinicalTrials.gov registry record · Phase 2
GM-CSF in Patients With Pulmonary Alveolar Proteinosis
A Phase 2 study, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00030056: Clinical Trial Phase 2 study, sponsored by The Cleveland Clinic.
NCT00030056 is a Phase 2 study that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 48 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00030056, a Phase 2 study, was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a study to determine the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered subcutaneously to patients with pulmonary alveolar proteinosis (PAP).
Interventions
- DRUG GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2001-09 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Why NCT00030056 stopped before completion
NCT00030056 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 1 intervention - of which GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim) is the first listed.
NCT00030056 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00030056 about?
NCT00030056 is a clinical study titled "GM-CSF in Patients With Pulmonary Alveolar Proteinosis". This is a study to determine the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered subcutaneously to patients with pulmonary alveolar proteinosis (PAP).
What is the current status of trial NCT00030056?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2001-09. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00030056?
The interventions under investigation include: GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim) (DRUG).
Who is sponsoring clinical trial NCT00030056?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00030056's enrollment target sits among peer trials
48 1265th of 2000 higher than 718 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia